Research location
Shelby
Michigan, United States
Advertisement
Research activity in Shelby
Michigan, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 22 trials and 22 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Shelby
22 linked trials · page 1 of 1Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487 · 2024-02-29 · 1 site observation
COMPLETED
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNCT04037254 · 2019-10-08 · 1 site observation
COMPLETED
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)NCT03811002 · 2019-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNCT03737994 · 2019-07-25 · 1 site observation
TERMINATED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaNCT03228537 · 2018-07-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · 2008-04-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.